The current standard care for patients with newly diagnosed KRAS-mutated NSCLC commonly involves an immune-checkpoint inhibitor (e.g., PD-1/PD-L1 inhibitor) as monotherapy or in combination with chemotherapy [111–113]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.